New drug study aims to control rare tumors in real patients
NCT ID NCT07272512
Summary
This study is testing how well an oral medication called surufatinib works for people with advanced neuroendocrine tumors in real-world medical settings. About 350 patients will take the medication daily and be monitored for tumor response, side effects, and quality of life. The goal is to gather evidence about the drug's effectiveness and safety to help doctors make better treatment decisions for this rare cancer type.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huadong Hospital Affiliated to Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Huashan Hospital Affiliated to Fudan University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital shanghai jiao tong university school of medicine
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.